Ruserontinib
Based on 1 Customer Validation
Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.32%
- CAS 番号: 1350544-93-2
- 分子式: C24H29N9
- 分子量:443.55
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
Ruserontinib (SKLB1028) can significantly inhibit the growth of mf4-11 cells expressing FLT3-ITD with IC50 value of 0.002 μM, inhibit the proliferation of RS4-11 cells expressing wt-FLT3 with IC50 value of 0.790 μM, and inhibit Ba The IC50 value for the growth of /F3 cells is 0.01 μM, and the IC50 value for inhibiting the growth of K562 cells expressing the Bcr-Abl mutant is 0.190 μM[1].
Ruserontinib (SKLB1028) (0-100 nM, 20 h) causes a dose-dependent decrease in the level of pro-caspase-3 in MV4-11 cells, while a dose-dependent increase in the level of the cleaved caspase-3 fragment, and can be dose-dependent Inhibits phosphorylation of STAT5 and Erk1/2 in a dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MV4-11 and K562 xenograft NOD-SCID models[1]
-
Dosage:5, 10, 20 mg/kg,70 mg/kg
-
Administration:orally once daily, 18 days
-
Result:Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg.
Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1350544-93-2
-
性状 Solid
-
分子量 443.55
-
分子式 C24H29N9
-
Color Off-white to yellow
-
SMILES
CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4N=C(N(C4=N3)C(C)C)NC5=CC=CN=C5
-
別名
SKLB1028
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 250 mg/mL (563.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2545 mL | 11.2727 mL | 22.5454 mL | 56.3634 mL |
| 5 mM | 0.4509 mL | 2.2545 mL | 4.5091 mL | 11.2727 mL | |
| 10 mM | 0.2255 mL | 1.1273 mL | 2.2545 mL | 5.6363 mL | |
| 15 mM | 0.1503 mL | 0.7515 mL | 1.5030 mL | 3.7576 mL | |
| 20 mM | 0.1127 mL | 0.5636 mL | 1.1273 mL | 2.8182 mL | |
| 25 mM | 0.0902 mL | 0.4509 mL | 0.9018 mL | 2.2545 mL | |
| 30 mM | 0.0752 mL | 0.3758 mL | 0.7515 mL | 1.8788 mL | |
| 40 mM | 0.0564 mL | 0.2818 mL | 0.5636 mL | 1.4091 mL | |
| 50 mM | 0.0451 mL | 0.2255 mL | 0.4509 mL | 1.1273 mL | |
| 60 mM | 0.0376 mL | 0.1879 mL | 0.3758 mL | 0.9394 mL | |
| 80 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7045 mL | |
| 100 mM | 0.0225 mL | 0.1127 mL | 0.2255 mL | 0.5636 mL |
Ruserontinib 関連分類
HY-120590 関連分類
Powered by Bioz